Nasdaq
$1.40▼ 2.78%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $30.6MShares out 21.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 23h agoPre-market26.10.23 21:388-KKey event#●●●#●●●#●●●
Aardvark Therapeutics, Inc.Bullish
AI summary pendingAardvark Therapeutics reported exploratory efficacy data from its previously terminated Phase 3 HERO and open-label extension (OLE) trials. Following the FDA's decision to lift the clinical hold on ARD-101, the company plans to align with the FDA on a new Phase 3 trial design and expects to resume clinical activities in 2027.…more
$1.40-2.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 1d agoAfter-hours26.10.23 05:178-KKey event
Aardvark Therapeutics, Inc.
The U.S. FDA has lifted the clinical hold on the Investigational New Drug application for ARD-101, intended for the treatment of hyperphagia in Prader-Willi Syndrome. Aardvark Therapeutics will resume clinical development and host an investor conference call on October 23, 2026, at 8:00 a.m. ET to review data from the terminated HERO and OLE trials.…more
$1.40-2.78%vs prev closeView filingShare - 10.8After-hours26.10.09 05:494Ownership
Aardvark Therapeutics, Inc.
Insider Zhang Zhongwei of Aardvark Therapeutics, Inc. filed a Form 4 report regarding changes in beneficial ownership of securities, effective October 7, 2026.…more
$1.40-2.78%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 20h agoRegular26.10.24 00:43Bullish#●●●#●●●
Aardvark Therapeutics Shares Plunge on Insufficient Clinical Data
Aardvark Therapeutics shares fell over 56% after the company released exploratory data from its terminated Phase 3 trial, which was deemed insufficient for definitive conclusions. Despite the FDA lifting a clinical hold on the drug, the company must now adjust dosing protocols to continue development.…more
$1.40-2.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 1d agoPre-market26.10.23 20:00
●●●●●●●● ●●●●● ●●●●●●
Aardvark Therapeutics released exploratory data from its prematurely terminated Phase 3 trial and plans to consult with the FDA to resume clinical activities. Due to the early termination, the data is not definitive, and the company's path forward depends on aligning with the FDA on a new trial design.…more
$1.40-2.78%vs prev close - 1d agoOvernight26.10.23 14:59
●●●●●●●● ●●●●● ●●●●●●
Aardvark Therapeutics announced that the FDA has lifted the clinical hold on its Prader-Willi syndrome drug candidate, ARD-101, following the resolution of cardiac safety concerns. This regulatory clearance restores the company's path to resume clinical development for the rare genetic disorder.…more
$1.40-2.78%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report